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To the Editor: It has been brought to the attention of the 
Executive Committee of the South African Paediatric 
Association that the intravenous form of phenobarbitone is no 
longer available in South Africa.
   In August 2004 Aventis informed all provincial authorities 
that the worldwide production of sodium gardenal would be 
stopped and that it would no longer be available once stocks 
had been depleted. 
   This is a matter of great concern in terms of treating children 
in South Africa, especially those who present with epilepsy, in 
particular status epilepticus. In general, as far as developing 
countries are concerned, the action of Aventis cannot be 
defended. It would have been far better had they made sure 
that alternative arrangements were available in Africa before 
unilaterally withdrawing sodium gardenal.
   Intravenous phenobarbitone has proved to be highly 
effective, it is safe and cheap, it can be given in repeated 
doses by rapid push-in, and it is currently recommended 
on all the international APLS guidelines for the treatment of 
status epilepticus. We have been informed that intravenous 
phenytoin or lorazepam are proposed alternatives. These drugs 
would not pose a problem in tertiary settings, but at primary 
and secondary level intravenous phenobarbitone is easy to 
administer with relatively few complications, and needs to be 
available.
   The decision by the World Health Organization (WHO) 
to remove intravenous phenobarbitone extensively without 
consultation in developing countries, especially in Africa, is 
also disconcerting. It is strongly advised that this matter be 
reconsidered and that dialogue be initiated with the WHO on 
this issue.
   Phenytoin and lorazepam have been suggested as 
alternatives. Intravenous phenytoin has to be administered 
over a long period of time via a syringe driver and requires 
an intravenous line, which may not always be possible in 
rural settings. Cardiac monitoring is recommended because of 
cardiac arrhythmias. It cannot be repeated once given and it 
may not be as affective as phenobarbitone.
   Lorazepam, on the other hand, is dangerous as a follow-
up after 2 doses of short-acting benzodiazepine because 
respiratory depression is very likely. Again, this would be a 
problem in primary and secondary settings where there are 
no facilities to ventilate children. It is also markedly expensive 
compared with intravenous phenobarbitone.
   It is therefore clear that intravenous phenobarbitone remains 
the mainstay of first-line treatment for status epilepticus, 
especially in the primary and secondary health care settings, 
where the majority of children in South Africa are managed. 
Phenobarbitone is still manufactured by alternative companies 
internationally and we would support efforts to have these 
products registered and distributed in South Africa as soon as 
possible.
   Currently intravenous phenobarbitone is available as a Sec- 
tion 21 medication, but this is not effective or useful for the fut- 
ure use of intravenous phenobarbitone for the children at risk.
   We urge the Department of Health to take cognisance of the 
problem, and we would support any initiative from the Central 
Department of Health to address this medical crisis in the 
management of status epilepticus in children.
Raziya Bobat
On behalf of the South African Paediatric Association Executive 
Committee
Department of Paediatrics and Child Health
Nelson R Mandela School of Medicine
University of KwaZulu-Natal
Durban
‘Found guilty’ – an unjust outcome?
To the Editor: A well-respected surgical colleague was recently 
found guilty by the Health Professions Council of South 
Africa (HPCSA) on 5 of 8 charges after complications arose 
from a laparoscopic procedure for gastric reflux. Sentence was 
delivered on Friday 14 October, where he was cautioned and 
discharged.
   As an anaesthesiologist I have witnessed many of these 
procedures by a wide variety of surgeons and my comments 
are based on personal experience.  Looking at those who 
made up the bench for this hearing (a general practitioner, 
a community medicine doctor and a retired surgeon), I’m 
surprised that they did not include a surgeon actively involved 
in this type of surgery. 
    Together with all my colleagues currently engaged in 
laparoscopic surgery in Cape Town, I am devastated by 
the outcome of the hearing. Knowing what happened, and 
the steps taken to manage events, we can only assume that 
inexperienced people are, unfairly to themselves, being 
appointed to sit at these hearings.
   The complications that arose in this case are well known 
to those involved in laparoscopic surgery. There is nothing 
disgraceful about a wrong clinical decision … it is human. 
The unfortunate surgeon, who is highly experienced in 
laparoscopic surgery and well respected by colleagues, 
both academic and private, acted in the best interests of the 
patient. He sought advice and the problem was eventually 
resolved. The patient had a traumatic postoperative course but 
fortunately survived the ordeal and I believe is now fit and 
healthy. I have a sneaking suspicion that this case represents an 
attack on laparoscopic surgery by those who seem to have very 
little insight into the specialty.
   A surgeon’s decision may not always be correct, but to be 
found guilty of unprofessional conduct and to be accused of 
belated surgical action, failing to recognise the clinical course 
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in the postoperative period and bringing the profession of 
specialist surgeon into disrepute is provocative and laughable. 
I’m surprised that this hearing favoured the ‘expertise’ 
presented by a retired surgical academic, who by his own 
admission had done very little laparoscopic surgery, over 
that of a professor and a specialist intensivist currently at the 
top of their careers.  Surely experienced medical personnel 
should be appointed to hear public grievances?  Those of us 
who are members of the Medical Protection Society (MPS) are 
concerned that in a case like this the legal representatives failed 
dismally. This case should have won hands down. 
   There is a perception among the lay public and litigation 
lawyers that as most of us have some form of medical prot- 
ection there’s no harm in ‘having a go’!  MPS reports suggest 
that medicolegal claims in South Africa have escalated way 
above rates in the rest of the world. It is my impression that 
we in clinical medicine are seen as an easily milked cash cow.  
We are under continual pressure from medical aids, hospital 
groups and the media – and now our very own HPCSA.
   I sincerely hope that the colleague in question has the 
stamina to exercise his rights and appeal against the findings of 
the HPCSA, and that his surgical association reacts strongly to 
this disgraceful decision.
Barry Penn
31 Mountain Road 
Claremont
7708
Well done, SAMA’s Industrial Relations 
Unit!
To the Editor: It is reassuring to know that the South African 
Medical Association, through its Industrial Relations Unit, 
has the capacity to assist doctors, especially hospital doctors, 
should any have reason to believe that they have been 
subjected to unfair labour practices. 
   My own experience is that about 3 years after retirement 
I was phoned by the hospital concerned and told that I had 
received a salary increase some 2 or 3 years before retirement 
for which I had not been paid. I was told that if I supplied my 
bank details I would be paid. Having heard nothing for a year 
I made further enquiries, only to be told that the provincial 
health department concern had no money.
   I had no recourse other than through the SAMA Industrial 
Labour Unit, which was entirely successful in obtaining my 
back pay.
  I don’t hesitate to recommend to all doctors that they should 
become SAMA members, for this and many other reasons!




Selective serotonin reuptake inhibitors 
in children and adolescents
To the Editor: The introduction of the selective serotonin 
reuptake inhibitors (SSRIs) was widely viewed as an important 
advance in clinical psychopharmacology, not only because 
of their broad-spectrum efficacy but also because of their 
tolerability and safety advantages, particularly compared with 
the older tricyclic antidepressants (TCAs) and monoamine 
oxide inhibitors (MAOIs). Subsequently there has been 
considerable controversy about this class of agents, partly 
because of concerns about the extent to which they have been 
injudiciously prescribed for ‘cosmetic’ problems rather than 
for genuine psychopathology,1 and partly because of concerns 
regarding their adverse effects. Most recently, attention has 
been paid to the appropriate use of SSRIs in children and 
adolescents.
   The ‘Drug Alert’ published by the National Adverse Drug 
Event Monitoring Centre in the September 2005 SAMJ2 is 
singularly unhelpful in this regard. The report takes a far more 
conservative stance than that taken by regulators in the USA, 
the UK and the EU; it may be misleading by implication and 
omission; and (if followed to the letter) it may cause child and 
adolescent psychiatric patients significant harm.
   The ‘Drug Alert’ warns practitioners on four points. First, 
‘None of the SSRIs are currently approved in South Africa 
for any indication in children and adolescents.’ It should 
be pointed out, however, that fluoxetine is registered with 
the US Food and Drug Administration (FDA) for child and 
adolescent depression and several of the SSRIs (fluvoxamine, 
sertraline, and fluoxetine) are also FDA-registered for child and 
adolescent obsessive-compulsive disorder (OCD).3 Practitioners 
should also be aware that decisions about whether to submit 
pharmaceutical agents to the Medicines Control Council for 
registration of particular indications may often be made on the 
basis of cost rather than scientific or clinical considerations.  
   Second, ‘SSRIs have been associated with an increase in the 
risk of suicidal thinking and behaviour (suicidality) in children 
and adolescents with MDD [major depressive disorder] and 
other psychiatric disorders.’ However, as the drug alert also 
states, ‘no suicides occurred’ in the 24 trials involving over 
4 400 patients. In addition, a systematic review4 published 
recently found no significant difference in the risk of suicide 
in patients taking SSRIs compared with those taking TCAs. 
As several commentators have pointed out, patients with 
overt suicidal ideation are excluded from clinical trials and 
the heterogeneous nature of the trial designs employed (use of 
different definitions and assessments of self-harm in different 
study populations) further contributes to the difficulty of 
interpreting the data. The trials quoted were not designed 
to address the question of whether SSRIs increase suicidal 
ideation, and cannot in fact do so.5
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